The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder
Neurourology and Urodynamics,
Год журнала:
2024,
Номер
43(8), С. 1742 - 1752
Опубликована: Июль 15, 2024
The
purpose
of
this
guideline
is
to
provide
evidence-based
guidance
clinicians
all
specialties
on
the
evaluation,
management,
and
treatment
idiopathic
overactive
bladder
(OAB).
informs
reader
valid
diagnostic
processes
provides
an
approach
selecting
options
for
patients
with
OAB
through
shared
decision-making
process,
which
will
maximize
symptom
control
quality
life,
while
minimizing
adverse
events
burden
disease.
Язык: Английский
A Comparison of U.S. Individual and Family Plan Medication Coverage for Overactive Bladder
Urogynecology,
Год журнала:
2024,
Номер
30(3), С. 214 - 222
Опубликована: Март 1, 2024
Importance
There
is
strong
evidence
for
long-term
cognitive
effects
with
anticholinergic
use.
Differences
in
insurance
coverage
of
anticholinergics
and
beta-3
agonists
hinder
individualization
overactive
bladder
(OAB)
treatment.
Objectives
The
aims
the
study
were
to
assess
individual
family
health
plan
select
OAB
medications
compare
preferred
those
a
greater
risk
dysfunction.
Study
Design
This
cross-sectional
analyzed
formularies
top
7
U.S.
medical
insurers.
Coverage
tiers
assessed
following
medications:
(1)
oxybutynin
instant-release
5
mg,
(2)
extended-release
(3)
solifenacin
(4)
trospium
20
(5)
60
(6)
mirabegron
25
(7)
vibegron
75
mg.
was
compared
between
nonpreferred
(oxybutynin,
solifenacin)
(trospium,
mirabegron,
vibegron).
scores,
representing
weighted
average
based
on
tier
frequency
relative
number
plans
investigated
each
state
or
insurer,
generated
lower
score
indicating
better
(range,
0.2–1.0).
Results
A
total
2,780
from
41
states
47%
market
share
marketplace
evaluated.
Oxybutynin
IR
had
best
across
insurers
(0.2)
while
worst
(0.92).
Preferred
more
often
designated
higher
worse
(
P
<
0.001).
Less
concordance
noted
specificity
formulations.
Conclusions
Despite
risks
anticholinergics,
expensive
all
highlighting
need
expanded
avoid
dysfunction
when
undergoing
treatment
OAB.
Язык: Английский
Trends in Medicare Coverage of Overactive Bladder Medications in the United States
Urogynecology,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 30, 2024
Strong
evidence
demonstrates
long-term
cognitive
decline
associated
with
anticholinergics.
While
prevalent
among
older
populations,
medical
management
of
overactive
bladder
(OAB)
is
dictated
by
insurance
coverage
rather
than
provider
and
patient
preferences.
The
aim
this
study
was
to
assess
Medicare
plan
for
select
OAB
medications
evaluate
preferred
a
greater
risk
dysfunction.
This
cross-sectional
analyzed
formularies
tiers
across
6
U.S.
insurers
the
following
medications:
oxybutynin
instant-release
(IR)
5
mg,
extended-release
(ER)
tolterodine
IR
1
ER
2
fesoterodine
4
darifenacin
7.5
solifenacin
trospium
20
60
mirabegron
25
vibegron
75
mg.
Coverage
compared
between
nonpreferred
(oxybutynin,
tolterodine,
fesoterodine,
darifenacin,
solifenacin)
(trospium,
mirabegron,
vibegron).
scores,
weighted
distribution
based
on
tier
frequency
relative
number
plans
investigated,
were
generated
lower
score
indicating
better
(range,
0.2-1.0).
One
thousand
six
hundred
nineteen
representing
an
estimated
47%
market
share
evaluated.
Oxybutynin
had
best
(0.4),
whereas
worst
(0.89).
Preferred
worse
versus
(P
<
0.001).
Centene
overall
lowest
initiation
cost,
Aetna/CVS
cost
medications.
Beta-3
agonists
nationwide.
Current
trends
in
reveal
need
improved
aging
population
already
at
Язык: Английский